Cargando…

Association of Receiving a Fourth Dose of the BNT162b Vaccine With SARS-CoV-2 Infection Among Health Care Workers in Israel

IMPORTANCE: Despite the high 3-dose vaccination rate among health care workers (HCWs) in Israel, a high rate of SARS-CoV-2 breakthrough infections in this group was observed during the Omicron wave. As a result, the Israeli Ministry of Health decided to recommend a fourth vaccine dose to medical sta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cohen, Matan J., Oster, Yonatan, Moses, Allon E., Spitzer, Avishay, Benenson, Shmuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346545/ https://www.ncbi.nlm.nih.gov/pubmed/35917125 http://dx.doi.org/10.1001/jamanetworkopen.2022.24657

Ejemplares similares

BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers
por: Benenson, Shmuel, et al.
Publicado: (2021)

The effect of a third BNT162b2 vaccine on breakthrough infections in health care workers: a cohort analysis
por: Oster, Yonatan, et al.
Publicado: (2022)

Association Between Exposure Characteristics and the Risk for COVID-19 Infection Among Health Care Workers With and Without BNT162b2 Vaccination
por: Oster, Yonatan, et al.
Publicado: (2021)

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2022)

Boosting capacity of a fourth dose BNT162b2 in cancer patients
por: Debie, Yana, et al.
Publicado: (2023)

A Dynamic Response to Exposures of Health Care Workers to Newly Diagnosed COVID-19 Patients or Hospital Personnel, in Order to Minimize Cross-Transmission and the Need for Suspension From Work During the Outbreak
por: Schwartz, Carmela, et al.
Publicado: (2020)

Is it financially beneficial for hospitals to prevent nosocomial infections?
por: Benenson, Shmuel, et al.
Publicado: (2020)

Immunogenicity and SARS-CoV-2 Infection following the Fourth BNT162b2 Booster Dose among Health Care Workers
por: Shachor-Meyouhas, Yael, et al.
Publicado: (2023)

Eight-Month Follow-up After the Third Dose of BNT162b2 Vaccine in Healthcare Workers: The Question of a Fourth Dose
por: Lim, Sung Hee, et al.
Publicado: (2023)

The Humoral Response of Patients With Cancer to Breakthrough COVID-19 Infection or the Fourth BNT162b2 Vaccine Dose
por: Cohen, Idan, et al.
Publicado: (2023)

Carriage of multi-drug resistant bacteria among foreigners seeking medical care
por: Benenson, Shmuel, et al.
Publicado: (2018)

Access-related infections in two haemodialysis units: results of a nine-year intervention and surveillance program
por: Gork, Ittamar, et al.
Publicado: (2019)

Waning Immunity after the BNT162b2 Vaccine in Israel
por: Goldberg, Yair, et al.
Publicado: (2021)

Short-Term Safety of Booster Immunization With BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers
por: Paran, Yael, et al.
Publicado: (2021)

Immunogenicity trends 1 and 3 months after second BNT162B2 vaccination among healthcare workers in Israel
por: Shachor-Meyouhas, Yael, et al.
Publicado: (2022)

Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose
por: Canetti, Michal, et al.
Publicado: (2022)

Proactive screening approach for SARS-CoV-2 among healthcare workers
por: Oster, Yonatan, et al.
Publicado: (2021)

Attitudes of Healthcare Workers in Israel towards the Fourth Dose of COVID-19 Vaccine
por: Ramot, Shira, et al.
Publicado: (2023)

Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 Years
por: Bar-Haim, Erez, et al.
Publicado: (2022)

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
por: Magen, Ori, et al.
Publicado: (2022)

SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis
por: Bensouna, Ilias, et al.
Publicado: (2022)

Analysis of Immunization, Adverse Events, and Efficacy of a Fourth Dose of BNT162b2 Vaccine in Health Workers in Mexico, a Pilot Study
por: Romero-Ibarguengoitia, Maria Elena, et al.
Publicado: (2022)

Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study
por: Yechezkel, Matan, et al.
Publicado: (2023)

Fourth dose of COVID-19 vaccines in Israel
por: Burki, Talha Khan
Publicado: (2022)

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2021)

Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization
por: Chodick, Gabriel, et al.
Publicado: (2021)

Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed?
por: Di Noia, Vincenzo, et al.
Publicado: (2022)

Deconstruction of central line insertion guidelines based on the positive deviance approach—Reducing gaps between guidelines and implementation: A qualitative ethnographic research
por: Cohen, Ricky, et al.
Publicado: (2019)

Translating a theory-based positive deviance approach into an applied tool: Mitigating barriers among health professionals (HPs) regarding infection prevention and control (IPC) guidelines
por: Cohen, Ricky, et al.
Publicado: (2022)

Antibody response to third and fourth BNT162b2 mRNA booster vaccinations in healthcare workers in Tokyo, Japan
por: Sanada, Takahiro, et al.
Publicado: (2023)

Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel
por: Regev-Yochay, Gili, et al.
Publicado: (2021)

Effects of BNT162b2 Covid-19 Vaccine Booster in Long-Term Care Facilities in Israel
por: Muhsen, Khitam, et al.
Publicado: (2021)

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel
por: Mevorach, Dror, et al.
Publicado: (2021)

Comparative Risk of Myocarditis/Pericarditis Following Second Doses of BNT162b2 and mRNA-1273 Coronavirus Vaccines
por: Naveed, Zaeema, et al.
Publicado: (2022)

Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer
por: Ligumsky, Hagai, et al.
Publicado: (2022)

Weaker Effects of the Fourth Dose of BNT162b2 SARS-CoV-2 Vaccine on the Elderly Human Population
por: Dimeglio, Chloé, et al.
Publicado: (2023)

Blunted humoral immune response to the fourth dose of BNT162b2 COVID-19 vaccine in patients undergoing hemodialysis
por: Kanai, Daisuke, et al.
Publicado: (2023)

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
por: Barda, Noam, et al.
Publicado: (2021)

BNT162b2 vaccination effectively prevents the rapid rise of SARS-CoV-2 variant B.1.1.7 in high-risk populations in Israel
por: Munitz, Ariel, et al.
Publicado: (2021)

Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantation
por: Peled, Yael, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8h5ol974mbvs598gep48b655gj